Oculis Holding ( (OCS) ) has provided an update.
On March 11, 2025, Oculis Holding AG announced its financial results for the fiscal year ending December 31, 2024, highlighting significant clinical advancements in its pipeline, including positive Phase 2 trial results for its treatments in diabetic macular edema, acute optic neuritis, and dry eye disease. The company completed a $100 million equity financing to support its late-stage clinical portfolio and plans to continue its strategic focus on advancing its pipeline, with significant cash reserves expected to fund operations into early 2028.
More about Oculis Holding
Oculis Holding AG is a global biopharmaceutical company focused on developing innovative treatments for ophthalmic and neuro-ophthalmic diseases, addressing significant unmet medical needs.
YTD Price Performance: 8.09%
Average Trading Volume: 76,431
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $878.4M
For a thorough assessment of OCS stock, go to TipRanks’ Stock Analysis page.